Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bone Marrow B Cell Response to Influenza Vaccine
NCT02485639Phase 4Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2015
- Primary completion
- Mar 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Fluzone Trivalent in influenza, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Influenza-specific Antibody Secreting Cells (ASC) Present in the Blood at Day 7, Number of Influenza-specific Antibody Secreting Cells (ASC) Present in the Bone Marrow at Day 365 and 3 more. Started Dec 2015; status: terminated.
02
Drugs
Fluzone Trivalent
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02485639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02485639.